<DOC>
	<DOC>NCT00433914</DOC>
	<brief_summary>To explore safety, Tolerability and immunogenicity of two formulations of a Meningococcal B Recombinant Vaccine when administered to healthy infants.</brief_summary>
	<brief_title>Safety, Tolerability and Immunogenicity of Two Different Formulations of Meningococcal B Recombinant Vaccine, When Administered to Healthy Infants</brief_title>
	<detailed_description />
	<mesh_term>Meningococcal Infections</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>healthy 68 months old infants previous receipt of any meningococcal B vaccine; previous ascertained or suspected disease caused by N meningitidis; history of any anaphylactic shock, asthma, urticaria or other allergic reaction after previous vaccinations or known hypersensitivity to any vaccine component; any present or suspected serious acute or chronic disease known or suspected autoimmune disease or impairment /alteration of immune function</criteria>
	<gender>All</gender>
	<minimum_age>6 Months</minimum_age>
	<maximum_age>8 Months</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>Meningococcal disease, prevention, vaccination</keyword>
</DOC>